Institutional investors may adopt severe steps after AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest 4.7% drop adds to a year losses
Key Insights Given the large stake in the stock by institutions, AbCellera Biologics' stock price might be vulnerable...